Biomarker for Cystic Fibrosis

CENTOGENE GmbH Rostock54 enrolled

Overview

International, multicenter, observational, longitudinal study to identify biomarker/s for Cystic fibrosis and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

Cystic fibrosis (CyFi) is a progressive hereditary disease with the prevalence of 1 in 2500. CyFi is an autosomal recessive disease caused by pathogenic variant/s in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene encoding Cftr protein. CyFi causes chronic respiratory damage. Pulmonary findings occur already in infancy, which raises questions whether obstruction might be congenital. Thick, sticky mucus clogs the airways, reduces muco-ciliary clearance and leads to problems with breathing and recurrent bacterial (Pseudomonas aeruginosa) infections, which causes over time the formation of scar tissue (fibrosis) and cysts in the lungs.There is no cure for CyFi; however, symptomatic treatment can help relieve symptoms. The aim of this study is to identify biomarkers for Cystic fibrosis disease and to explore their clinical robustness, specificity, and long-term variability. An ideal biomarker plays an essential role in the early diagnosis, prediction and therapeutic monitoring of a specific disorder.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chronic Nasal Congestion Lung Infection Breathlessness Clubbing Toes Meconium Ileus Failure to Thrive Pancreatitis

Eligibility

Sex: ALLMin age: 2 MonthsMax age: 50 Years

Medical Language ↔ Plain English

INCLUSION CRITERIA: * Informed consent is obtained from the participant or the parent/ legal guardian * The participant is aged between 2 months and 50 years * The diagnosis of Cystic fibrosis is genetically confirmed by CENTOGENE EXCLUSION CRITERIA: * Informed consent is not obtained from the participant or from the parent/ legal guardian * The participant is younger than 2 months or older than 50 years * The diagnosis of Cystic fibrosis is not genetically confirmed by CENTOGENE

Locations (5)

University Hospital Center Mother Teresa

Tirana, Albania

Department of Molecular and Medical Genetics, Tbilisi State Medical University

Tbilisi, Georgia

Amrita Institute of Medical Sciences & Research Centre

Kochi, Kerala, India

Department of Pediatric Gastroenterology and Hepatology, The Children's Hospital and Institute of Child Health

Lahore, Pakistan

Outcomes

Primary Outcomes

Identification of Cystic fibrosis biomarker/s

All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC

Time frame: 36 months

Secondary Outcomes

Exploring the clinical robustness, specificity, and long-term variability of Cystic fibrosis biomarker/s

Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.

Time frame: 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.